CClinicalTrials.gg
Status unknownNCT03903848Updated Apr 4, 2019

Cancer Survivors Acute Exercise Response 1

An interventional study of Exercise in Neoplasms Malignant, sponsored by University of Houston. Status unknown. Open to participants aged 40 Years to 70 Years. Per ClinicalTrials.gov, last updated 2019-04-04.

Sponsored by University of Houston · Not applicable, Interventional, and Other

The sponsor has not verified this record recently (last verified Apr 2019), so the status shown — last known as Not yet recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
40 Years to 70 Years
Sex
All
01

Study summary

The aims of this study examine the immune system, muscle metabolism, and autonomic nervous system response to an acute bout of exercise. Cancer survivors will participate in an acute bout of exercise. Blood samples will be collected before the exercise bout and at two time points after the exercise bout to assess the proposed variables.

02

Conditions studied

  • Neoplasms Malignant

Browse trials for

03

In context

Neoplasms

9,365 studies on the registry are indexed under Neoplasms; 2,489 are open to participants now.

This study's planned enrollment of 18 is below the median of 50 across 7,253 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

University of Houston is the lead sponsor of 101 studies on the registry; 17 are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 3 (33%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Between the ages of 40-70 years

    • At least two years past detectible cancer (two years disease-free survival)
    • Have received chemotherapy and/or radiation as part of their cancer treatment
    • All cancers were of the organs/non-blood producing tissues (not blood/hematologic cancers) and while they were an adult (no history of pediatric cancer)
    • Meeting ACSM-AHA guidelines for exercise (150 minutes per week of cardiorespiratory fitness type exercises and \~two days per week of resistance training), as confirmed by a combination of a physical activity questionnaire and a cardiorespiratory fitness classification of "good" or higher (age and sex matched)
    • A BMI between 20-33 kg·m-2
    • Able to speak and read English

Exclusion criteria

Exclusion Criteria:

Participants may not:

  • Have any contraindications to moderate to vigorous exercise
  • Have any recent illness or have been instructed not to exercise by a healthcare provider
  • Participants may not have range of motion restrictions that would prevent them from participating in aerobic or resistance training with proper form (they must be ambulatory)
  • Be taking medications (prescription or over the counter) known to influence immune function (including daily NSAID's and beta blockers), cholesterol-lowering medications (statins), drugs that increase bone mass (bisphosphonates), or steroids.
  • Have known cardiovascular, respiratory, metabolic, or renal disease, with the exception of controlled hypertension (as defined by resting BP below 140/90) and/or controlled asthma (self-reported).
  • Be pregnant
  • Be unable to complete all visits (i.e. must not be planning to leave the Houston area long-term before concluding their participation in the study)
  • Fall outside of a BMI range of (20 - 33)
  • Consume alcohol or recreational drugs for 24h prior to visits
  • Participants must not have scheduling conflicts that would prevent them from reporting to the laboratory of integrated physiology 2-3 times over the course of the study
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (estimated)

Study arms

  • Experimental
    Exercise session

    One session of physical exercise

    Other: Exercise

Interventions

  • OtherExercise

    Single session of treadmill walking and resistance exercise

06

What researchers measure

Primary outcomes

  1. Exercise-induced response of circulating monocytes

    Circulating serum monocyte phenotype before and after one exercise session

    Time frame: Pre-exercise, change from pre-exercise to immediately post-exercise, change from pre-exercise to 1hr post-exercise, change from immediately post-exercise to 1hr post-exercise

  2. Exercise-induced response of circulating T cells

    Circulating serum T cells phenotype before and after one exercise session

    Time frame: Pre-exercise, change from pre-exercise to immediately post-exercise, change from pre-exercise to 1hr post-exercise, change from immediately post-exercise to 1hr post-exercise

  3. Exercise-induced response of circulating Follistatin

    Circulating serum follistatin before and after one exercise session

    Time frame: Pre-exercise, change from pre-exercise to immediately post-exercise, change from pre-exercise to 1hr post-exercise, change from immediately post-exercise to 1hr post-exercise

  4. Exercise-induced response of circulating GDF-15

    Circulating serum growth differentiation factor 15 before and after one exercise session

    Time frame: Pre-exercise, change from pre-exercise to immediately post-exercise, change from pre-exercise to 1hr post-exercise, change from immediately post-exercise to 1hr post-exercise

Secondary outcomes

  1. Body composition

    Relative body composition, as calculated from a DEXA scan. Measurement will be used as a descriptive variable and potential covariant

    Time frame: before exercise

  2. Body weight

    Absolute body weight as measured with an eye level beam. Measurement will be used as a descriptive variable and potential covariant

    Time frame: before exercise

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — IPD may be shared if publication journal requires data sharing

Supporting information: Study protocol, Sap

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 4, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03903848
Lead sponsor
University of Houston
Responsible party
Melissa M Markofski (Assistant Professor, University of Houston) — Principal investigator
First posted
Apr 4, 2019
Start date
Jul 1, 2019 (estimated)
Primary completion
Dec 31, 2020 (estimated)
Completion
Dec 31, 2023 (estimated)
Last update
Apr 4, 2019

Study contacts

Melissa Markofski, PhD
Contact
mmarkofski@uh.edu
7137436658
Melissa M Markofski
principal investigator · University of Houston

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion